SKP2 and cancer: Apart from targeting Skp2, development of specific inhibitors targeting Akt upstream regulators, such as TRAF6, SETDB1 and JMJD2A, may also serve as a novel and innovative strategy for eradicating hyperactive Akt-driven human cancers.